Glenmark Life Sciences Limited
Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and m… Read more
Glenmark Life Sciences Limited (GLS) - Total Liabilities
Latest total liabilities as of September 2024: ₹5.46 Billion INR
Based on the latest financial reports, Glenmark Life Sciences Limited (GLS) has total liabilities worth ₹5.46 Billion INR as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Glenmark Life Sciences Limited - Total Liabilities Trend (2018–2024)
This chart illustrates how Glenmark Life Sciences Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Glenmark Life Sciences Limited Competitors by Total Liabilities
The table below lists competitors of Glenmark Life Sciences Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SIMPAR S.A
SA:SIMH3
|
Brazil | R$78.00 Billion |
|
Beijing Deep Glint Technology Co. Ltd. A
SHG:688207
|
China | CN¥113.59 Million |
|
Inox Wind Limited
NSE:INOXWIND
|
India | ₹27.50 Billion |
|
Asseco South Eastern Europe S.A.
WAR:ASE
|
Poland | zł1.30 Billion |
|
EVN Finance JSC
VN:EVF
|
Vietnam | ₫73.18 Trillion |
|
Prudent Corporate Advisory Services Limited
NSE:PRUDENT
|
India | ₹2.57 Billion |
|
São Martinho S.A
SA:SMTO3
|
Brazil | R$15.84 Billion |
|
StarHub Ltd
F:RYTB
|
Germany | €2.50 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Glenmark Life Sciences Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Glenmark Life Sciences Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Glenmark Life Sciences Limited (2018–2024)
The table below shows the annual total liabilities of Glenmark Life Sciences Limited from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-03-31 | ₹5.18 Billion | -8.13% |
| 2023-03-31 | ₹5.64 Billion | +35.34% |
| 2022-03-31 | ₹4.17 Billion | -66.51% |
| 2021-03-31 | ₹12.44 Billion | -6.01% |
| 2020-03-31 | ₹13.24 Billion | -4.57% |
| 2019-03-31 | ₹13.87 Billion | +93444.84% |
| 2018-03-31 | ₹14.83 Million | -- |